Leerink Reiterates Outperform on Boston Scientific (BSX) After CHAMPION-AF Readout

Boston Scientific Corporation (NYSE:BSX) is one of the 8 Most Oversold Strong Buy-Rated Stocks to Invest In.

On March 30, 2026, Leerink analyst Mike Kratky said Boston Scientific Corporation (NYSE:BSX) CHAMPION-AF readout met both primary safety and efficacy endpoints, as expected, with results presented at ACC. Mike Kratky noted some nuances in the data that bears may focus on, but said feedback from physicians and key opinion leaders supported confidence in increased WATCHMAN procedure volumes. Mike Kratky described the outcome as not a “home run,” but said the data could support incremental adoption and around 20% growth over the LRP, while adding that shares may remain sensitive to near-term dynamics. Leerink reiterated an Outperform rating on the stock.

Similarly, Wells Fargo said the CHAMPION-AF results were “good, not great,” noting the data is unlikely to accelerate WATCHMAN growth due to a slightly higher ischemic stroke rate. Wells Fargo said the device was non-inferior to oral anticoagulants on the primary endpoint but performed worse numerically on stroke rates, leading the firm to lower estimates while maintaining an Overweight rating.

Leerink Reiterates Outperform on Boston Scientific (BSX) After CHAMPION-AF Readout

Robert Kneschke/Shutterstock.com

On March 29, 2026, Boston Scientific announced the CHAMPION-AF global clinical trial met all primary and secondary safety and efficacy endpoints. The study evaluated the WATCHMAN FLX device against non-vitamin K antagonist oral anticoagulants in patients with non-valvular atrial fibrillation. The trial enrolled 3,000 patients and showed a 45% relative reduction in non-procedural bleeding risk, and a 34% reduction when including procedural bleeding. The primary efficacy endpoint was also met, with the device achieving statistical non-inferiority compared to oral anticoagulants.

Boston Scientific Corporation (NYSE:BSX) develops, manufactures, and markets medical devices for interventional medical specialties worldwide.

While we acknowledge the risk and potential of BSX as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than BSX and that has 10,000% upside potential, check out our report about this cheapest AI stock.

READ NEXT: 33 Stocks That Should Double in 3 Years and Cathie Wood 2026 Portfolio: 10 Best Stocks to Buy. 

Disclosure: None. Follow Insider Monkey on Google News.